SCHEDULE 13G/A: Fairmount Funds Management Fully Divests Stake in Kiniksa Pharmaceuticals
Ownership Disclosure
Fairmount Funds Management LLC and its affiliates have fully divested their 5.3% beneficial ownership in Kiniksa Pharmaceuticals International, plc, holding zero shares as of the filing date.
Summary
- This document is Amendment No. 3 to a Schedule 13G filing by Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak (collectively, the "Reporting Persons") concerning their ownership in Kiniksa Pharmaceuticals International, plc.
- As of December 31, 2024, the Reporting Persons' beneficial ownership in Kiniksa Pharmaceuticals International, plc consisted of 2,194,341 Class A Ordinary Shares, representing 5.3% of the class outstanding.
- As of the filing date, February 14, 2025, the Reporting Persons hold no shares of Kiniksa Pharmaceuticals International, plc, indicating a complete divestment of their stake.
- Fairmount Funds Management LLC acts as the investment adviser for Fairmount Healthcare Fund II L.P., and Peter Harwin and Tomas Kiselak are managing members of Fairmount Funds Management LLC.
Sentiment
Score: 2
Explanation: The complete divestment of a significant stake by an institutional investor is a strong negative signal, indicating a lack of confidence in the company's future performance or a shift in investment strategy away from the company.
Negatives
- Fairmount Funds Management LLC and its affiliates have completely divested their 5.3% beneficial ownership in Kiniksa Pharmaceuticals International, plc.
- The Reporting Persons, who previously held 2,194,341 shares, now hold 0 shares as of the filing date.
Risks
- The complete divestment by a significant institutional investor like Fairmount Funds Management LLC could be interpreted as a signal of decreased confidence in Kiniksa Pharmaceuticals International, plc's future prospects.
- This divestment may contribute to negative market sentiment and potential downward pressure on the company's stock price.
Stakeholder Impact
- Shareholders: The complete divestment by a significant institutional investor may lead to decreased investor confidence and potential downward pressure on the stock price due to the perceived loss of institutional support.
Key Dates
| Date | Description |
|---|---|
| 2023-08-10 | Original Schedule 13G filing date. |
| 2024-02-14 | Amendment No. 1 to Schedule 13G filing date. |
| 2024-11-14 | Amendment No. 2 to Schedule 13G filing date. |
| 2024-12-31 | Date of event which required this filing, when beneficial ownership was 5.3%. |
| 2025-02-14 | Date of this Amendment No. 3 filing, when beneficial ownership became 0%. |
Recommendation
sellKeywords
Kiniksa Pharmaceuticals, Fairmount Funds Management, Schedule 13G, Beneficial Ownership, Share Divestment, Institutional Investor, Class A Ordinary Shares, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.